Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Chord Therapeutics

Request full access

Developing drugs for patients with rare, life-threatening, and severely disabling diseases

Geneva, SwitzerlandFounded 2014Biotech & Life Sciences

About Chord Therapeutics

Chord Therapeutics is a clinical-stage pharmaceutical company focused on repurposing established molecules for new applications in rare, debilitating neuroinflammatory diseases.

The company was founded in 2014 by Dr. Arthur Roach, who identified the potential of cladribine to address significant unmet needs in rare autoimmune disorders. Dr. Roach has a background in neurodegenerative disease research, previously serving as Senior Director at Serono (now Merck). The company officially launched in October 2020, securing a USD 16 million Series A financing exclusively from healthcare investor Omega Funds. This funding propelled the company into its next phase of clinical development. The management team was led by CEO Tom Plitz, who brought experience from his prior role as Chief Scientific Officer at Wilson Therapeutics, another rare disease-focused company.

Chord's primary business strategy centers on de-risking drug development. It identifies active substances with well-documented safety and pharmacology profiles and applies them to new indications where there is a strong scientific rationale. This approach significantly lowers development risk and timelines. The company operates on a lean, virtual biotech model, outsourcing clinical development services to specialized vendors to maintain agility and cost-efficiency.

The company's lead asset was CRD1, an oral formulation of cladribine. Cladribine is a well-understood molecule known for selectively targeting B and T lymphocytes, which are key drivers in autoimmune diseases. Chord aimed to develop CRD1 for two primary indications: generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD), both of which are severe, life-threatening orphan diseases. The U.S. FDA had granted CRD1 orphan drug designation for these conditions.

In December 2021, just over a year after its official launch, Chord Therapeutics was acquired by Merck. The acquisition provided a strategic expansion of Merck's neurology pipeline, building on its existing expertise with cladribine in multiple sclerosis. The transaction, which closed in early 2022, enabled Merck to take over and accelerate the development of oral cladribine for gMG and NMOSD, leveraging its extensive resources to bring the potential therapy to patients faster.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
1
Open positions
None listed
Dealroom signal
57.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Dec 2021 $0 — Merck KGaA ↗
SERIES A✓Equity / VC Oct 2020 $16M $64M Omega Funds —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Chord Therapeutics website traffic

Latest recorded traffic for Chord Therapeutics is 230 monthly website visits, down 20.7% over the last three months. Chord Therapeutics's team grew 0% over the past year.

Latest monthly visits230 3-month web change-20.7% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Chord Therapeutics in the Geneva ecosystem

Live from Dealroom

The Chord Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Eclosion

Series A1 investor entered at this stage

  • Omega Funds

Other known investors1 additional known investor

  • Merck KGaA
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇭 Switzerland · Geneva HQ
Book a demo for the full country breakdown

See Chord Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.